Low-intensity extracorporeal shock wave therapy in the rehabilitation treatment of fibroplastic penile induration (peyronie’s disease)

Authors:

Gubanov Evgeniy Sergeevich, urologist, PhD in Medical sciences, Associate Professor of the Department of Surgical Diseases, Medical University “Reaviz”, 227 Chapaevskaya Street, 443001 Samara, Russian Federation, e-mail: samara- urology@mail.ru

Boryaev Evgeny Aleksandrovich, urologist of the Multidisciplinary Clinic REAVIZ, Medical University “Reaviz”, 227 Chapaevskaya Street, 443001 Samara, Russian Federation, e-mail: boriaev.evgeny@yandex.ru

Stolyarov Sergey Anatolyevich, MD, Head of the Department of Surgical Diseases, Medical University “Reaviz”, 227 Chapaevskaya Street, 443001 Samara, Russian Federation, e-mail: stolyarovsamara@mail.ru

Kachkovskiy Mikhail Arkadievich, MD, Professor, Professor of the Department of Internal Diseases, Medical University “Reaviz”, 227 Chapaevskaya Street, 443001 Samara, Russian Federation, E-mail: KachkovskyMA@reaviz.ru

Kanaev Evgeny Igorevich, urologist, assistant of the Department of Operative Surgery, Samara State Medical University, 89 Chapaevskaya Street, 443099 Samara, e-mail: kanaevei@gmail.com

Annotation:

Introduction. Fibroplastic induration of the penis or Peyronie’s disease is the disease with poorly understood etiology and pathogenesis.

Aim. Examination and treatment of 20 patients 25–66 years old (mean age 45.5±4.3 years) with Peyronie’s disease were carried out.

Materials and methods. 20 patients aged 25–66 years (mean age 45.5±4.3 years) with Peyronie’s disease were examined and treated. They complained of curvature of the penis, weakening of erection, pain during erection, the appearance of induration in the area of the penis. The time from the onset of the disease was 3–6 months.

Results and discussion. The angle of curvature of the penis reached 30 degrees in 6 patients (30%), in 14 patients (70%) the curvature was absent or insignificant. Plaques from 0.7 to 2 cm in length were identified by palpation.
Mild erectile dysfunction was revealed in 6 patients (30 %) when questioned on the International Index of Erectile Function (IIEF-5) scale, 9 patients (45%) had moderate impairments, in 5 patients (25%) there were no impairments. Vascular disorders were detected by Doppler ultrasound in 9 patients (45%) with moderate erectile dysfunction. Low-intensity extracorporeal shock wave therapy for the penis in the area of the plaque was used as the main treatment method. All patients showed positive dynamics as a result of treatment: MIEF-5 increased by an average of 5 points, the maximum angle of curvature of the penis decreased and did not exceed 23 degrees, and all patients noted the disappearance of pain during sexual intercourse.

Conclusion. The use of low-intensity extracorporeal shock wave therapy is a promising conservative method for the treatment of fibroplastic induration of the penis, with a high safety profile.

List of cited literature:

1. Moskaleva YU.S., Ostapchenko A.Yu., Korneev I.A. Bolezn’ Pejroni // Urologicheskie vedomosti.- 2015.- Tom V, №4.- S.30-35 [Moskaleva YuS., Ostapchenko AYu, Korneev IA. Peyronie’s disease. Urological statements. 2015; V(4): 30-5] (In Russian).

2. Chung E, Gillman M, Rushton D, Love C, Katz D. Prevalence of penile curvature: a population-based cross-sectional study in metropolitan and rural cities in Australia. BJU Int. 2018; 122 Suppl 5:42-49.

3. Ostrowski KA, Gannon JR, Walsh TJ. A review of the epidemiology and treatment of Peyronie’s disease. Res Rep Urol. 2016; 8:61-70.

4. Al-Thakafi S, Al-Hathal N. Peyronie’s disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up. Transl Androl Urol 2016; 5(3):280-9.

5. Stuntz M, Perlaky A, des Vignes F, Kyriakides T, Glass D. The Prevalence of Peyronie’s Disease in the United States: A Population-Based Study. PLoS One, 2016; 11(2): e0150157.

6. Hussein AA, Alwaal A, Lue TF. All about Peyronie’s disease. Asian J Urol. 2015; 2(2): 70-78.

7. Ventimiglia E., Capogrosso P., Colicchia M., Boeri L. Peyronie’s disease and autoimmunity-a real-life clinical study and comprehensive review. J Sex Med 2015; 12(4):1062-9.

8. Bilgutay AN, Pastuszak AW. Peyronie’s disease: What’s around the bend. Indian J Urol. 2016; 32(1):6-14.

9. Kadioglu, A., Tefekli A., Erol B. et al. A retrospective review of 307 men with Peyronie’s disease. J Urol 2002; 168(3): 1075-9.

10. Mulhall, J.P., et al. An analysis of the natural history of Peyronie’s disease. J Urol, 2006. 175: 2115.

11. Berookhim, B.M., Choi D., Alex B. et al. Deformity stabilization and improvement in men with untreated Peyronie’s disease // BJU Int 2014; 113(1): 133-6.

12. Pryor JP, Ralph DJ. Clinical presentations of Peyronie’s disease. Int J Impot Res, 2002; 14: 414-7.

13. Nelson, CJ, Diblasio C, Kendirci M. et al. The chronology of depression and distress in men with Peyronie’s disease. J Sex Med, 2008; 5(8):1985-90.

14. Russo GI, Milenkovic U, Hellstrom W et al. Clinical Efficacy of Injection and Mechanical Therapy for Peyronie’s Disease: A Systematic Review of the Literature. Eur Urol, 2018; 74(6):767-781.

15. Masterson TA, Rezk A, Ramasamy R. Characteristics predictive of response to collagenase clostridium histolyticum for Peyronie’s disease: a review of the literature. World J Urol, 2020; 38(2): 279-285.

16. Nguyen H.M.T., Anaissie J, DeLay KJ et al. Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment of Acute-Phase Peyronie’s Disease. J Sex Med, 2017; 14(10):1220-1225.

17. Kadioglu A, Tefekli A., Erol B. et al. Color Doppler ultrasound assessment of penile vascular system in men with Peyronie’s disease. Int J Impot Res, 2000; 12(5):263-7.

18. Gholami SS, Gonzalez-Cadavid NF, Lin CS et al. Peyronie’s disease: a review. J Urol, 2003; 169(4):1234-41.

19. Chung, E., et al. Evidence-Based Management Guidelines on Peyronie’s Disease. J Sex Med 2016; 13(6):905-23.

20. Muller, A, Mulhall JP et al. Peyronie’s disease intervention trials: methodological challenges and issues. J Sex Med; 2009; 6(3):848-61.

21. Nehra A, Alterowitz R, Culkin DJ et al. Peyronie’s Disease: AUA Guideline. J Urol, 2015; 194(3):745-53.

22. Bella AJ, Lee JC, Grober ED et al. 2018 Canadian Urological Association guideline for Peyronie’s disease and congenital penile curvature. Can Urol Assoc J, 2018 ;12(5):E197-E209.

23. Dahm P, Jung JH, Bodie J. Moving from Consensus- to Evidence-Based Clinical Practice Guidelines for Peyronie’s Disease. J Sex Med, 2017; 14(1):170-171.

24. Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F. A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie’s disease. BJU Int. 2010; 106(2):240-8.

25. Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F. Retraction statement: A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie’s disease. BJU Int. 2015; 115(3): E10.

26. Liu T, Shindel AW, Lin G, Lue TF. Cellular signaling pathways modulated by low-intensity extracorporeal shock wave therapy. Int J Impot Res. 2019; 31(3):170-176.

27. Palmieri A, Imbimbo C, Creta M et al. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl 2012; 35(2): 190-5.

28. Hatzichristodoulou G, Meisner C, Gschwend JE et al. Extracorporeal shock wave therapy in Peyronie’s disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med 2013; 10(11): 2815-21.

29. Gao L, Qian S, Tang Z, Li J, Yuan J. A meta-analysis of extracorporeal shock wave therapy for Peyronie’s disease. Int J Impot Res. 2016; 28(5):161-6.

30. Shheplev P.A., Danilov I.A., Kolotinskij A.B i dr. Klinicheskie rekomendacii. Bolezn’ Pejroni // Andrologiya i genital’naya hirurgiya. – 2007. – №1. – S. 55–58. [Scheplev PA, Danilov IA, Kolotinsky AB, et al. Clinical guidelines. Peyronie’s disease. Andrology and genital surgery. 2007; (1): 55-58] (In Russian).

31. Kasenova BZH, Notov I K, Verdiev RV. i dr. Aktual’nye voprosy patogeneza, diagnosticheskoj vizualizacii i metodov lecheniya bolezni Pejroni // Vestnik Rossijskogo universiteta druzhby narodov. Seriya: Medicina.- 2020.- T. 24, № 1.- S. 9—25. [Kasenova BZh, Notov IK, Verdiev RV. and others. Topical issues of pathogenesis, diagnostic imaging and treatment methods of Peyronie’s disease. Bulletin of the Peoples’ Friendship University of Russia. Series: Medicine 2020; 24(1): 9—25] (In Russian).

32. Nehra A, Alterowitz R, Culkin DJ et al. Peyronie’s disease: AUA guideline. J Urol. 2015; 194(3): 745-53.

33. Nejmark A.I., Astahov Yu.I., Sidor M.V. Primenenie ekstrakorporal’noj udarno-volnovoj terapii v lechenii bolezni Pejroni // Urologiya.- 2004.- №2.- S.33-36 [Neimark AI, Astakhov Yu I, Sidor MV. The use of extracorporeal shock wave therapy in the treatment of Peyronie’s disease. Urology 2004, (2): 33-6] (In Russian).

34. Pakus O.I. Effektivnost’ distancionnoj udarno-volnovoj terapii pri bolezni Pejroni. Avtoreferat diss. na soiskanie uch. stepeni kand. med. nauk / Moskovskaya akademiya im. I.M.Sechenova. Moskva, 2005.- 24 s. [Pakus OI Effectiveness of external shock wave therapy in Peyronie’s disease. Abstract dissertation PhD / Moscow Academy. I.M.Sechenov. Moscow, 2005: 24 p.] (In Russian).

35. Vinogradov I.V., Logvinov L.A., Kumachev K.V. i dr. Opyt primeneniya udarno-volnovoj terapii pri bolezni Pejroni // Andrologiya i genital’naya hirurgiya.- 2011.- №3.- S.27-31 [Vinogradov IV, Logvinov LA., Kumachev KV. et al. Experience in the use of shock wave therapy in Peyronie’s disease. Andrology and Genital Surgery. 2011; (3): 27-31] (In Russian).

36. Garilevich B.A., Kirpatovskij V.I., Semenov A.A., Kudryavceva L.V. Eksperimental’noe obosnovanie primeneniya akusticheskih udarnyh voln nizkih energij v terapii razlichnyh urologicheskih zabolevanij // Eksperimental’naya i klinicheskaya urologiya.- 2018.- №2.-S.4-10 [Garilevich BA, Kirpatovsky VI, Semenov AA, Kudryavtseva LV. Experimental substantiation of the use of low-energy acoustic shock waves in the treatment of various urological diseases. Experimental and Clinical Urology. 2018; (2): P.4-10] (In Russian).